Phio Pharmaceuticals Corp. — Company profile
Healthcare · Biotechnology · United States
Last price 0.8626 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Details
| Name | Phio Pharmaceuticals Corp. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6 |
| Founded | 2003 |
| Ceo | Robert Bitterman |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US71880W5013 |
| Cusip | 71880W501 |
| Cik | 0001533040 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer and Chairman |
| Lisa C. Carson | Chief Financial Officer, Principal Accounting Officer and Vice President of Finance and Administration |
| Linda M. Mahoney | Senior Vice President of Development |
| Dr. Jennifer Phillips Pharm.D. | Senior Vice President of Regulatory and Corporate Affairs |
Contact
| Address | 411 Swedeland Road, Suite 23-1080, King of Prussia, Pennsylvania 19406, United States |
| Phone | 610 947 0251 |
| Website | https://phiopharma.com |